ImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its ... MarketWatch (press release) Today NHL is frequently treated with the anticancer antibody, rituximab (Rituxan(R)), and/or with chemotherapy. The novel agent IMGN529, a TAP compound, contains a B-cell-targeting antibody that has demonstrated marked anticancer activity in ... |
